MRNA Vaccine Benefits Outweigh Heart Risks, CDC Reports
(Bloomberg) -- The benefits of messenger RNA Covid-19 vaccines clearly outweigh the risks despite heart complications seen in a relatively small number of mostly young men, according to the U.S. Centers for Disease Control and Prevention.
Roughly 1,200 cases of myocarditis, or inflammation of the heart wall, were reported in people who received mRNA vaccines, the CDC said in its Morbidity and Mortality Weekly Report on Tuesday. But with about 296 million doses of mRNA vaccines having been administered as of June 11, the benefit is clear in all populations, including adolescents and young adults, the researchers reported.
Vaccines made by Moderna Inc. and the Pfizer Inc.-BioNTech SE partnership are the only mRNA inoculations authorized for emergency use in the U.S. The issue was first explored in a June 23 meeting of the CDC's Advisory Committee on Immunization Practices.
There has been increasing concern that these possible cardiovascular side effects could threaten vaccine uptake among young Americans as the highly transmissible delta variant is hitting under-vaccinated hot spots of the country.
The agency report said that fact sheets should be provided before mRNA vaccinations. The U.S. Food and Drug Administration Emergency Use Authorization has been modified to include information on myocarditis after receipt of mRNA Covid-19 vaccines.
©2021 Bloomberg L.P.
-
India's Troika Of Good Luck | Joining The Dots
A weaker Trump, a cooling AI trade and resilient earnings have put Indian markets back in favour. Rising inflation could spoil the party.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.